Tagraxofusp-erzs




Tagraxofusp-erzs Overview

Tagraxofusp, sold under the brand name Elzonris, is a medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018.[2] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[3] Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.[4][1] The fusion protein readily kills culture...

Read more Tagraxofusp-erzs Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tagraxofusp-erzs

Recent Tagraxofusp-erzs Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tagraxofusp-erzs
  • Solution: 1000mcg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Tagraxofusp-erzs or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 2 December 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA